Menu
Menu
Menu
Telum Therapeutics Development Pipeline
Within our pipeline we have specific programs to treat serious multidrug-resistant
Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa
Program / Product
Pathogen
Discovery
Preclinical
Patent
Ongoing
Future
P001(GN EPLE)
Acinetobacter baumannii CRA
Serious infections
Patent application underwriting
P002 (GP EPLE)
Enterococcus faecium VRE
Nosocomial infections
P003 (GN&GP EPLE)
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Cystic Fibrosis
P004 (GN EPLE)
Escherichia coli CRE & ESBL-producing
Complicated urinary tract infections (UTIs)
PCT/EP2021/056564
P005 (GN EPLE)
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
Serious infections and Skin infections
Program / Product
P001 (GN EPLE)
Pathogen
Acinetobacter baumannii CRA
Discovery & Preclinical
Serious infections
Patent
Patent application underwriting
Program / Product
P002 (GP EPLE)
Pathogen
Enterococcus faecium VRE
Discovery & Preclinical
Nosocomial infections
Patent
Program / Product
P003 (GN&GP EPLE)
Pathogen
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Discovery & Preclinical
Cystic Fibrosis
Patent
Program / Product
P004 (GN EPLE)
Pathogen
Escherichia coli CRE & ESBL-producing
Discovery & Preclinical
Complicated urinary tract infections (UTIs)
Patent
PCT/EP2021/056564
Program / Product
P005 (GN EPLE)
Pathogen
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
Discovery & Preclinical
Preclinical
Serious infections and Skin infections
Patent
Abbreviations: EPLE: Engineered Phage Lytic Enzyme; GN, Gram negative bacteria; GP, Gram positive bacteria; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp
